MyFinsight
Home
Blog
About
Contact
Download
Download image
Maturities of investments
$74,500K
Proceeds from issuance of
common stock under the...
$86K
Proceeds from exercise of
stock options
$27K
Net cash provided by
investing activities
$28,311K
Net cash provided by
financing activities
$113K
Canceled cashflow
$46,189K
Net (decrease)
increase in cash and cash...
-$1,410K
Canceled cashflow
$28,424K
Stock-based compensation
expense
$6,246K
Prepaid expenses and
other assets
-$1,512K
Accrued compensation
$742K
Other current
liabilities
$438K
Other non-current
liabilities
$170K
Purchases of investments
$46,189K
Net cash used in
operating activities
-$29,834K
Canceled cashflow
$9,108K
Net loss
-$35,174K
Accrued liabilities
-$2,402K
Net accretion of
discount on investments
$1,070K
Accounts payable
-$296K
Back
Back
Cash Flow
source: myfinsight.com
AN2 Therapeutics, Inc. (ANTX)
AN2 Therapeutics, Inc. (ANTX)